Global Medtech Trends 2026: Trade, Supply Chains, and Market Restructuring

Executive Summary

The global medical technology (medtech) sector is undergoing a structural transformation driven by pricing reforms in China, shifting care settings in the United States, supply chain reconfiguration, and the rise of platform-based competition. These trends are not isolated; they carry significant implications for international trade, cross-border investment, and the resilience of global supply chains. This analysis examines five key medtech trends identified in Clarivate's "Medtech Trends to Watch in 2026" and explores their broader impact on global commerce and industrial strategy.

Introduction

The medtech industry has long been a bellwether for global trade and innovation. Yet as 2026 approaches, the sector faces a confluence of forces that are redefining market access, manufacturing footprints, and competitive dynamics. From mainland China's evolving procurement policies to the accelerating shift of procedures to outpatient settings, from tariff-driven supply chain realignment to the disruptive influence of GLP-1 therapies, medtech companies must navigate a more complex and interconnected global economy.

This feature article, based on Clarivate's e-book "Medtech Trends to Watch in 2026," provides a strategic analysis of these developments from the perspective of international business and trade intelligence. It examines how these trends affect exporters, importers, investors, and policymakers, and outlines the long-term implications for global trade and industrial competitiveness.

Main Analysis

1. China's VBP Expansion Reshapes Global Pricing and Market Access

Mainland China's volume-based procurement (VBP) program, initially designed to improve patient access and reduce costs, has evolved into a powerful market-structuring mechanism. The latest national VBP rounds introduce more sophisticated anchor-price logic, deeper price compression, and allocation systems that favor domestic manufacturers. For multinational medtech companies, this is no longer a localized policy issue. It is influencing pricing expectations, volume commitments, and competitive positioning in markets well beyond China's borders.

From a global trade perspective, VBP signals a shift toward value-based purchasing in emerging markets. Multinationals must recalibrate their portfolio strategies, potentially segmenting products by market tier and revisiting their willingness to compete on price. The policy also accelerates domestic innovation, as local manufacturers gain a larger share of the market and reinvest in R&D. For international firms, this means forming partnerships or facing margin erosion in one of the world's largest healthcare markets.

2. Outpatient and ASC Settings Redefine Procedure Economics Across Borders

The migration of procedures from hospitals to outpatient settings, particularly ambulatory surgical centers (ASCs), is accelerating in the United States. The Centers for Medicare & Medicaid Services (CMS) 2026 OPPS/ASC Final Rule expands the ASC Covered Procedure List and phases out the inpatient-only list, enabling higher-acuity procedures such as cardiac ablation to move to lower-cost settings.

While this is primarily a US regulatory development, its ripple effects are global. Medtech companies with international operations must adapt their commercial models to serve diverse sites of care, not just hospitals. This shift influences product design, pricing strategies, and the value proposition of devices. For global manufacturers, the ability to navigate differing regulatory environments and payment systems becomes a competitive advantage. Additionally, the trend toward outpatient care is evident in other developed economies, suggesting a broader convergence of care delivery models.

3. Supply Chain Pressures and Tariffs Drive Manufacturing Diversification

Supply chain resilience has emerged as a strategic imperative in medtech. Tariff exposure, geopolitical tensions, and volatile material costs are challenging long-held assumptions about where and how devices are produced. Companies are now diversifying sourcing, re-evaluating offshoring strategies, and pursuing multi-region manufacturing footprints.

This trend has significant implications for global trade and investment. As medtech companies shift production closer to key markets or adopt a "China-plus-one" strategy, they are contributing to the broader reshoring and nearshoring movement. This affects trade flows, logistics networks, and the geography of foreign direct investment (FDI). Governments seeking to attract medtech manufacturing must consider infrastructure, regulatory harmonization, and the availability of skilled labor. The push for supply chain resilience is also driving investment in automation and digital technologies, which could reshape the competitiveness of various regions.

4. GLP-1 Therapies Alter Care Pathways and Device Demand

The rapid adoption of glucagon-like peptide-1 (GLP-1) receptor agonists for weight management is reshaping patient behavior and clinical pathways. While bariatric surgery remains the most effective intervention for substantial weight loss, GLP-1s are changing referral patterns and influencing demand for adjacent device categories. The impact varies by procedure type and therapy area, with downstream effects on diabetes care, sleep apnea, and cardiovascular monitoring.

For medtech companies, this represents both a threat and an opportunity. Some bariatric procedures are experiencing volume pressure, but new markets are emerging for devices that complement or monitor GLP-1 therapy. From a trade perspective, the GLP-1 effect underscores the convergence of pharmaceuticals and medical devices, blurring traditional industry boundaries. This may lead to new cross-sector partnerships and deal-making, as well as changes in how medical products are bundled and reimbursed.

5. Platform-Based Competition Redefines Medical Technology Ecosystems

Enabling technologies—including robotics, imaging, navigation, and digital workflow software—are no longer adjuncts to procedures. They are becoming central to integrated ecosystems that support clinical planning, surgical execution, and postoperative care. Companies are investing heavily in platform architectures that anchor entire service lines and unlock data-driven value propositions.

This shift toward platform-based competition has profound implications for global trade. As medtech firms develop proprietary ecosystems, they may seek to protect their intellectual property and data flows, leading to new trade frictions. It also intensifies competition around standards and interoperability, potentially creating regional blocs. For international businesses, understanding these technological dynamics is essential for strategic planning, whether as a competitor, partner, or investor.

Global Trade Impact

The five trends described above collectively influence global trade in several ways:

Pricing and Market Access: China's VBP expansion pressures multinationals to adopt new pricing models in emerging markets, potentially affecting export revenues and market share.
Supply Chain Reconfiguration: Tariffs and geopolitical risks are driving companies to diversify manufacturing, impacting global supply chain networks, logistics demand, and trade corridors.
Investment Flows: The need for resilience is spurring FDI in new production facilities, digital infrastructure, and regional logistics hubs.
Regulatory Divergence: Moves toward outpatient care and platform-based technologies may lead to divergent regulatory standards across markets, creating compliance burdens and trade barriers.
Cross-Sector Convergence: GLP-1 therapies highlight the blurring of pharma and medtech, potentially leading to new trade categories and cross-border collaboration.

These impacts extend beyond the medtech sector, offering insights into the future of global healthcare trade and the broader shift toward more resilient, digitized supply chains.

Strategic Insights

Diversification as a Strategic Priority: Medtech companies must treat supply chain diversification as a core business strategy, not just a risk mitigation exercise. This involves mapping suppliers, investing in regional capabilities, and exploring near-shoring opportunities.
Value-Based Market Access: Success in China and other VBP markets requires a value-based approach, where companies demonstrate clinical and economic benefits that justify premium pricing. This may involve partnering with local players or developing tailored product portfolios.
Platform Investments: Investing in enabling technologies and open platform ecosystems can create long-term competitive advantage, but requires significant capital and organizational change. International partnerships may be necessary to gain access to regional markets and expertise.
Policy Engagement: Medtech companies and trade associations should actively engage with policymakers to shape trade agreements, regulatory harmonization, and procurement rules. Intellectual property protection and data governance will be critical issues.
Opportunities in Emerging Markets: The GLP-1 effect and the shift to outpatient care create opportunities for device makers that can adapt to new care settings and support chronic disease management in emerging markets.

Future Outlook

Looking ahead to the next 3–5 years, these trends are likely to deepen and converge. We anticipate several developments:

Continued Price Pressure in Asia: VBP-style procurement will likely expand to other therapeutic categories and other Asian markets, forcing global medtech firms to rethink their pricing architectures.
Greater Supply Chain Localization: Regionalized manufacturing and supplier diversification will become the norm, with companies aiming to reduce dependency on any single country. This will boost intra-regional trade and investment.
Digital Integration: The adoption of AI, real-world data, and digital workflows will accelerate, enabling more efficient and personalized care. Trade in digital health services and data will rise, creating new challenges for data protection and cybersecurity.
Ecosystem Partnerships: Medtech companies will increasingly form alliances with tech firms, pharma companies, and healthcare providers to build integrated solutions. This could reshape the competitive landscape and lead to new forms of cross-border collaboration.
Policy and Trade Frictions: Divergent regulations on data, AI, and medical devices could become new sources of trade tension. The medtech sector will need to advocate for alignment and interoperability.

Key Takeaways

China's VBP expansion is redefining global pricing dynamics and market access, necessitating adaptive strategies for multinational medtech firms.
The shift to outpatient and ASC settings is transforming procedure economics, with implications for product design, commercialization, and global care delivery.
Supply chain resilience is now a strategic requirement, driving manufacturing diversification and influencing international trade and investment patterns.
GLP-1 therapies are altering care pathways and creating both disruptions and opportunities across multiple device markets.
Platform-based competition is emerging as the new battleground, requiring investments in robotics, imaging, and digital workflows.
These trends highlight the growing interconnection between healthcare and global trade, with policy decisions in one market having far-reaching effects.

Conclusion

The medtech industry stands at the nexus of global trade and healthcare innovation. As pricing pressures, supply chain demands, and technological shifts reshape the sector, companies must adopt a more strategic and internationally aware approach. By understanding these five trends, business leaders, investors, and policymakers can better navigate the complexities of the global medtech market and position themselves for long-term success.

---

This analysis is based on publicly available information from Clarivate's "Medtech Trends to Watch in 2026" (Clarivate, 2025). The original report provides detailed data and expert insights. For further reading, visit Clarivate's website.